26685-47-2

Upstream product

• 26685-45-0 2-benzyl-8-(1,2-dimethylheptyl)-10-hydroxy-5-oxo-1,2,3,4-tetrahydro-5H-[1]benzopyrano[4,3-c]pyridine 
• 917-64-6 methyl magnesium iodide 
• 271242-28-5 2-[1-benzyl-4-(1-hydroxy-1-methyl-ethyl)-1,2,5,6-tetrahydro-pyridin-3-yl]-5-(1,2-dimethyl-heptyl)-benzene-1,3-diol 
• 26685-45-0 2-benzyl-8-(1,2-dimethyl-heptyl)-10-hydroxy-1,2,3,4-tetrahydro-chromeno[4,3-c]pyridin-5-one 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 
• 10436-52-9 5-(1,2-dimethyl-heptyl)-benzene-1,3-diol 
• 26685-45-0 2-benzyl-8-(1,2-dimethyl-heptyl)-10-hydroxy-1,2,3,4-tetrahydro-chromeno[4,3-c]pyridin-5-one 
• 10436-52-9 5-(1,2-dimethyl-heptyl)-benzene-1,3-diol 
• 26685-45-0 2-benzyl-8-(1,2-dimethyl-heptyl)-10-hydroxy-1,2,3,4-tetrahydro-chromeno[4,3-c]pyridin-5-one 
• 10436-52-9 5-(1,2-dimethyl-heptyl)-benzene-1,3-diol 
• 26685-45-0 2-benzyl-8-(1,2-dimethyl-heptyl)-10-hydroxy-1,2,3,4-tetrahydro-chromeno[4,3-c]pyridin-5-one 
• 10436-52-9 5-(1,2-dimethyl-heptyl)-benzene-1,3-diol 

Downstream Products

• 26685-53-0 5,5-dimethyl-8-(1,2-dimethylheptyl)-10-hydroxy-1,2,3,4-tetrahydro-5H-[1]benzopyrano[4,3-c]pyridine 
• 26685-57-4 SP 1 
• 26685-57-4 8-(1,2-dimethyl-heptyl)-5,5-dimethyl-2-prop-2-ynyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-ol 
• 26685-57-4 8-(1,2-dimethyl-heptyl)-5,5-dimethyl-2-prop-2-ynyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-ol 
• 26685-57-4 8-(1,2-dimethyl-heptyl)-5,5-dimethyl-2-prop-2-ynyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-ol 
• 26685-57-4 8-(1,2-dimethyl-heptyl)-5,5-dimethyl-2-prop-2-ynyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-ol 
• 29019-49-6 8-(1,2-dimethyl-heptyl)-5,5-dimethyl-2-phenethyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-ol 
• 26685-58-5 2-cyclobutylmethyl-8-(1,2-dimethyl-heptyl)-5,5-dimethyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-ol 
• 58019-92-4 10-acetoxy-2-allyl-8-(1,2-dimethyl-heptyl)-5,5-dimethyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridine 

Relevant academic research and scientific papers

Soft cannabinoid analogues as potential anti-glaucoma agents

Cannabinoids have intraocular pressure (IOP) lowering effects, thus, they have a therapeutic potential in the treatment of glaucoma. Unfortunately, in the same time, they show CNS and cardiovascular effects as well. Our aim was to develop a safer, cannabi

Drugs derived from cannabinoids. 1. Nitrogen analogs, benzopyranopyridines and benzopyranopyrroles

Various nitrogen analogs of Δ(6a,10a) tetrahydrocannabinol were synthesized by a general procedure described in an earlier communication. Minimum effective doses (MED(50's)) and lethal doses (LD(50's)) were determined by a modified Irwin mouse screen afte